𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Model Generic Licenses: Cooperation and Competition

✍ Scribed by John Cox


Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
92 KB
Volume
26
Category
Article
ISSN
0098-7913

No coin nor oath required. For personal study only.

✦ Synopsis


This article is an interim report on a project commissioned by the worldΓ•s major subscription agents: the development of a suite of model licenses of electronic content to libraries. The use of primary journals in electronic form is a relatively recent event; both publishers and librarians are feeling their way. New business models may emerge, and model licenses will have to provide language that reßects new developments as they emerge.

The driving force behind generic licenses is a recognition of the need for a predictable environment in which model language can be found and used to express the outcome of most negotiations, whatever that outcome might be. The variety of licenses that both publishers and vendors offer contain much that is common in substance but different in expression. As a result, legal counsel is required to review each licenseΓ‘a time-consuming and expensive process. If acceptable wording can be found to express the many variables that can emerge from negotiation, then the process can be shortened and speeded up.

With this in mind, Þve subscription agents commissioned John Cox Associates to develop a set of models, or Γ’precedents.


πŸ“œ SIMILAR VOLUMES


Cooperation and competition
✍ Marina Roseman πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 115 KB

## Abstract Faculty self‐interest in the graduate school gives a prospective teacher second thoughts about entering the teaching profession.

Competition and cooperation in space
✍ Donna A. Demac; Ann McKay πŸ“‚ Article πŸ“… 1985 πŸ› Elsevier Science 🌐 English βš– 399 KB
Entry and competition in generic biologi
✍ Henry G. Grabowski; David B. Ridley; Kevin A. Schulman πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 189 KB

## Abstract Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologics can and should be treated like pharmaceuticals with regard to generics. In contrast with pharmaceuticals, which are manufactured through chemi